Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epistaxis01:30

Epistaxis

683
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
683
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

825
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
825
Chronic Pharyngitis01:23

Chronic Pharyngitis

13.9K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
13.9K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.4K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Highlights-August 2026.

International journal of dermatology·2026
Same author

Editor's Highlights-July 2026.

International journal of dermatology·2026
Same author

Editor's Highlights-June 2026.

International journal of dermatology·2026
Same author

Editor's Highlights-May 2026.

International journal of dermatology·2026
Same author

Editor's Highlights-April 2026.

International journal of dermatology·2026
Same author

Multidisciplinary aspects of pediatric cochlear implantation: anesthesiological considerations.

Cochlear implants international·2026

Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.7K

Rhinophototherapy in persistent allergic rhinitis.

Zsolt Bella1, Ágnes Kiricsi2, Éva Dósa-Rácz Viharosné3

  • 1Department of Otorhinolarygology and Head and Neck Surgery, Faculty of Medicine, University of Szeged, Tisza Lajos krt 111, Szeged, 6725, Hungary. dr.bella.zsolt@gmail.com.

European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
|November 20, 2016
PubMed
Summary

Rhinolight® intranasal phototherapy effectively reduced persistent allergic rhinitis symptoms and improved nasal airflow. This safe treatment option showed sustained benefits for patients after a 6-week course.

Keywords:
Intercellular adhesion molecule-1 expressionIntranasal phototherapyMucociliary clearanceNasal inspiratory peak flowPersistent allergic rhinitisRhinolight®

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

3.1K

Related Experiment Videos

Last Updated: Mar 11, 2026

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.7K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

3.1K

Area of Science:

  • Otolaryngology
  • Allergy and Immunology
  • Photomedicine

Background:

  • Previous studies indicated Rhinolight® intranasal phototherapy's efficacy and safety in intermittent allergic rhinitis.
  • Persistent allergic rhinitis requires effective and safe treatment options.

Purpose of the Study:

  • To evaluate the safety and effectiveness of Rhinolight® intranasal phototherapy for persistent allergic rhinitis.
  • To compare Rhinolight® treatment outcomes against a placebo in patients with persistent allergic rhinitis.

Main Methods:

  • A randomized controlled trial involving 34 patients with persistent allergic rhinitis.
  • Treatment involved 13 sessions of Rhinolight® (UV-B, UV-A, visible light) or placebo (low-intensity white light) over 6 weeks.
  • Outcome measures included symptom diaries, nasal inspiratory peak flow, smell threshold, mucociliary function, and ICAM-1 expression.

Main Results:

  • Significant improvements in nasal symptom scores and nasal inspiratory peak flow were observed in the Rhinolight® group compared to placebo.
  • These improvements were maintained for 4 weeks post-treatment.
  • No significant changes in smell or mucociliary function were noted; ICAM-1 expression showed a non-significant decrease.

Conclusions:

  • Rhinolight® intranasal phototherapy is a safe and effective treatment for persistent allergic rhinitis.
  • The therapy demonstrates sustained efficacy in improving key rhinitis symptoms and nasal airflow.